NOLVADEX 25 - Hutech Labs

Originally designed to treat hormone-sensitive breast cancers, tamoxifen citrate is classified as a SERM, acting as an estrogen antagonist in breast tissue. Developed by ICI (now AstraZeneca), it was FDA-approved in 1977. Tamoxifen’s structure allows it to selectively block estrogen in certain tissues while promoting estrogenic effects in others, such as the liver. Its influence on cholesterol levels makes it unique among anti-estrogen drugs. In sports, tamoxifen is used to prevent estrogen-related side effects from anabolic steroid cycles, maintaining a leaner, more defined physique​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about NOLVADEX 25 by Hutech Labs, consult with your doctor or healthcare professional.